BioNano Genomics

BioNano Genomics is a publicly traded company (NASDAQ: BNGO) rather than a privately capitalized firm. Its funding comes from equity markets, debt instruments, and revenue from instrument and consumable sales. The firm does not operate as a family office or manage third-party capital.

The firm sells integrated hardware-software workflows for optical genome mapping. The product line includes the Stratys and Saphyr instruments, the Ionic purification system, and the VIA analysis platform. Primary customers are clinical cytogenetics labs, academic medical centers, and biopharma quality-control teams.

Optical genome mapping images ultra-long DNA molecules to detect structural variants — deletions, duplications, inversions, and translocations — that range from 500 base pairs to chromosome-arm scale. DNA sequencing excels at single-nucleotide variants and small indels but frequently misses large structural rearrangements and fails in highly repetitive regions that OGM resolves.

No. BioNano Genomics is a life-sciences tools company, not an investment firm. There is no evidence of an affiliated family office, venture arm, or direct-investment vehicle.

BioNano’s marketing focuses on hematological-malignancy workups, solid-tumor profiling, constitutional genetic disease (including prenatal and neurodevelopmental disorders), and cell-line genomic-integrity testing for cell and gene therapy manufacturing. Over 500 publications cite its systems across these applications.